• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

    11/14/24 12:30:15 PM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    SC 13G/A 1 p24-3021sc13ga.htm PRENETICS GLOBAL LTD

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Prenetics Global Limited

    (Name of Issuer)
     

    Class A Ordinary Shares, par value $0.0015 per share

    (Title of Class of Securities)
     

    G72245122

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. G7224512213G/APage 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    Genetel Bioventures Limited

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Hong Kong SAR

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    613,786 Class A Ordinary Shares

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    613,786 Class A Ordinary Shares

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    613,786 Class A Ordinary Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

     

    CUSIP No. G7224512213G/APage 3 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    Michael Yang Mengsu

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    China

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    613,786 Class A Ordinary Shares

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    613,786 Class A Ordinary Shares

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    613,786 Class A Ordinary Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. G7224512213G/APage 4 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Prenetics Global Limited (the “Company”).  

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company’s principal executive offices are located at Unit 703-706, K11 Atelier King’s Road 728 King’s Road, Quarry Bay, Hong Kong.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This Statement is filed on behalf of Genetel Bioventures Limited (“Genetel”), a Hong Kong private limited company and Michael Yang Mengsu (“Mr. Yang Mengsu”), the controlling shareholder of Genetel (collectively, the “Reporting Persons”).

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The principal business office of each of the Reporting Persons is 7B Yardley Commercial Building, 3 Connaught Road West, Sheung Wan, Hong Kong.

     

    Item 2(c). CITIZENSHIP:
       
      Genetel is a Hong Kong private limited company. Mr. Yang Mengsu is a citizen of China (Hong Kong SAR).

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A ordinary shares, par value $0.0015 per share (the “Shares”).

     

    Item 2(e). CUSIP NUMBER :
       
      G72245122

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      Not applicable.

     

    Item 4. OWNERSHIP:
       
      The percentage used herein is calculated based upon 10,636,254 Shares outstanding as of April 24, 2024, as reported in the Company’s Annual Report of Foreign Private Issuers on Form 20-F for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on May 1, 2024.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person and is incorporated herein by reference.
       
      The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.

     

    CUSIP No. G7224512213G/APage 5 of 6 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following:  ¨

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. G7224512213G/APage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE: November 14, 2024

     

     

    GENETEL BIOVENTURES LIMITED  
       
       
    By: /s/ George William Hunter Cautherley  
    Name: George William Hunter Cautherley  
    Title: Director  
         
         
         
    By: /s/ Michael Yang Mengsu  
    Name: Michael Yang Mengsu  

     

     

    Get the next $PRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

      David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

      4/9/25 9:00:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

      Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

      3/18/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics to Participate in the 37th Annual ROTH Conference

      CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

      3/11/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Financials

    Live finance-specific insights

    See more
    • Prenetics Announces Third Quarter 2024 Financial Results

      Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

      11/27/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Second Quarter 2024 Financial Results

      Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

      10/7/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

      Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

      8/19/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/14/24 12:30:15 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      2/5/24 6:05:14 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/27/23 6:05:43 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

      1/18/23 7:56:45 AM ET
      $PRE
      Blank Checks
      Finance
    • Citigroup initiated coverage on Prenetics Group Ltd.

      Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

      7/12/22 11:48:35 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

      LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

      7/1/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

      (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

      2/9/24 9:25:22 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    SEC Filings

    See more
    • SEC Form S-8 filed by Prenetics Global Limited

      S-8 - Prenetics Global Ltd (0001876431) (Filer)

      5/7/25 8:47:19 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 20-F filed by Prenetics Global Limited

      20-F - Prenetics Global Ltd (0001876431) (Filer)

      4/30/25 4:44:18 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 6-K filed by Prenetics Global Limited

      6-K - Prenetics Global Ltd (0001876431) (Filer)

      3/5/25 8:34:06 AM ET
      $PRE
      Blank Checks
      Finance